Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes

被引:12
作者
Gimeno-Orna, Jose Antonio
Molinero-Herguedas, Edmundo
Sanchez-Vano, Raquel
Lou-Arnal, Luis M.
Boned-Juliani, Beatriz
Castro-Alonso, Francisco J.
机构
[1] Alcaniz Hosp, Dept Internal Med, Teruel, Spain
[2] Alcaniz Hosp, Dept Biochem, Teruel, Spain
关键词
diabetic nephropathies; cardiovascular diseases; risk factors;
D O I
10.1016/j.diabres.2006.03.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We attempted to assess whether microalbuminuria conferred the same cardiovascular risk as overt CVD in type 2 diabetic patients. Material and methods: A prospective cohort study including 436 type 2 diabetic patients (64.8 +/- 9.2 years old) without proteinuria, with follow-up until any cardiovascular event occurred, was performed. Patients were classified into four groups: group 0, non baseline CVD and normoalbuminuria; group 1, non baseline CVD and microalbuminuria; group 2, baseline CVD and normoalbuminuria; group 3, baseline CVD and microalburninuria. Cox's multivariate regression models were used to assess the risk ratio (RR) associated with each variable. Results: The median follow-up time was 7.6 years. Incidence rates of cardiovascular events per 1000 patient-years increased from groups 0 to 3 (23.8, 63.4, 74.1, 85.6; p < 0.0001). Multivariate RR for incident CVD in groups 1, 2 and 3 in relation to group 0 were 2.8 (95% confidence interval (CI) 1.7-4.6; p < 0.0001), 2.7 (95% CI 1.6-4.6; p < 0.0001) and 2.9 (95% CI 1.6-5.4; p = 0.001), respectively. No significant differences were seen between groups 1 and 2. Conclusions: We suggest that patients with microalburninuria are at very high vascular risk and should share the same objectives of a vascular risk-factor control as patients with overt CVD. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 27 条
[1]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[4]  
Collins R, 2003, LANCET, V361, P2005
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus - A systematic overview of the literature [J].
Dinneen, SF ;
Gerstein, HC .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (13) :1413-1418
[7]   PREVALENCE OF MICROALBUMINURIA AND MACROALBUMINURIA, ARTERIAL-HYPERTENSION, RETINOPATHY AND LARGE VESSEL DISEASE IN EUROPEAN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS [J].
GALL, MA ;
ROSSING, P ;
SKOTT, P ;
DAMSBO, P ;
VAAG, A ;
BECH, K ;
DEJGAARD, A ;
LAURITZEN, M ;
LAURITZEN, E ;
HOUGAARD, P ;
BECKNIELSEN, H ;
PARVING, HH .
DIABETOLOGIA, 1991, 34 (09) :655-661
[8]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[9]  
Gerstein HC, 2000, LANCET, V355, P253
[10]  
Gimeno Orna J A, 2002, An Med Interna, V19, P336